The abstract is read at the publisher; the summary is JClub's.
In 56 acute myeloid leukemia patients, AML-CAPP-Seq plasma ctDNA enabled universal MRD assessment with a median of 30.5 tracked variants per patient.
- Why it matters: Relapsed or refractory AML drives most deaths, and clinicians need broadly applicable, high-sensitivity MRD detection that can also monitor evolving tumor clones.
- What they did: The study used a personalized hybrid-capture deep-sequencing assay combining canonical AML drivers with patient-specific variants from whole-exome sequencing, comparing plasma ctDNA with matched blood and bone marrow compartments and SOC MRD methods.
- The result: Plasma ctDNA MRD more strongly predicted relapse-free survival (HR 17.8; P < 0.0001) and overall survival (HR 17; P < 0.0001) than SOC, and in 29 transplant recipients improved relapse risk stratification (HR 36; P = 0.0009).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.